What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Slides:

Advertisements

Similar presentations

Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.

Advertisements

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,

UK clinical perspective on treatment reviews of multiple sclerosis therapies Alasdair Coles Neurologist, Cambridge, UK.

Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.

FREEDOMS II TRIAL.

Fingolimod Therapy for Multiple Sclerosis

By Matthew Sampson. Overview What is it? Previous Treatments Monoclonal Antibodies Chimeric Molecules Oral Therapies Hematopoietic Stem Cells Future.

Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.

A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis Timothy L. Vollmer, MD Professor, Neurology and Neuroscience.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Anti-CD25 Antibody Daclizumab in the Inhibition.

Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience.

Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.

In The Name of God. Multiple Sclerosis and Normal MRI new modalities for problems solving.

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease C Bjartmar, J.R Wujek, B.D Trapp Journal of.

RIS CIS CDMS SPMS Long-term disability progression

Four Known Types of MS Clinically isolated syndrome (CIS)

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Overweight and Obesity: Validation as a Chronic Disease

Highlights From the 2015 European Multiple Sclerosis Meeting

Highlights From the 2017 Annual European MS Meeting

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Applying Real-World Evidence in MS: Reviewing the State of the Art

Perspectives on Key MS Data From the Annual Neurology Meeting

T-Cell Directed Therapy in MS

Challenges in Managing Progressive Multiple Sclerosis

Assessing Disease Progression in MS Treatment

Figure 3 Proportion of patients for whom NEDA

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

Are We Closer to Personalized Medicine in MS?

Should I Stay or Should I Go?

Program Goals Disclaimer Overview Assessing Disease Activity.

Remote Patient Management:

Treating to Target in MS

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Preventing Clinical Events in PAH

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Imaging in Liver Malignancy

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Clinical Pearls on Hot Topics in MS

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Emerging Multiple Sclerosis Therapies

Improving Outcomes in Patients With SSc-ILD

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Oral Therapies in MS.

Novel Therapeutics in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Pulmonary Arterial Hypertension and Hospitalizations

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Understanding the Role of Disability in MS Management

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.

Selective Immunomodulation in MS

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Brain Atrophy/Neurodegeneration: A Neuropathologist Perspective

Brain Volume Change: Under Multiple Influences

Brain Atrophy/Neurodegeneration: A Clinical Perspective

Pathological Causes of Brain Atrophy in MS

Mechanisms of Neurodegeneration in MS

Correlation Between Focal and Diffuse Pathological Changes

Detection of Brain Atrophy in MS Patients Using Imaging Techniques

Common Measures for Whole Brain and Regional Brain Atrophy

Brain Atrophy Is Related to Long-Term Disability in RRMS

GM and WM Volume Changes in Early RRMS

Pseudoatrophy After DMT Treatment

Effect of BRACE Therapies On Brain Volume Loss

Brain Volume Loss Outcomes: Results From the AFFIRM Trial

Alemtuzumab Brain Volume Loss Through Year 5

Teriflunomide Reduced Annual Brain Volume Loss Over 2 years in the TEMSO Study*

Reduction in PBVC With DMF: Significant in DEFINE But Not CONFIRM

ENDORSE Extension Trial Results

Fingolimod: Summary of Brain Volume Loss Data in FREEDOMS, FREEDOMS II, and TRANSFORMS

Sustained Reduction in Brain Volume Loss Over 4 Years

PREFERMS: Phase 4 Patient Outcomes on Fingolimod versus Platform Injectable DMTs

Contribution of Individual Components of NEDA-4 on Proportion of Patients Achieving NEDA

Predictive Value of NEDA for Disease Outcomes Over 6 Years

Types of Inflammation in MS

Evidence for Direct CNS Effects

Adding Brain Volume Loss to the Modified Rio Score System

Persistent MRI Lesion Activity and Brain Volume Loss as Predictors of Long-Term Disability Progression

Conclusions

Abbreviations

Abbreviations (cont)